DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20173267

Meldonium: drug which brought disrepute to sport

Bikash Ranjan Meher, Smita Das, Rashmi Ranjan Mohanty

Abstract


World of sports have been rocked by doping scandals every now and then and World Anti-Doping Agency(WADA) has banned several offending drugs at different times to counter this menace. Meldonium is the recent addition to the long list of drugs banned by WADA to prevent its misuse among the athletes. Meldonium is a carnitine synthesis inhibitor and has been approved by some European countries for the management of cardiac diseases like angina pectoris and congestive cardiac failure. Apart from these, it has numerous other indications like bronchial asthma, bronchitis and retinopathies. It had also been used by athletes across the world because of its presumptive role in increasing the performance.


Keywords


Doping, L-Carnitine, Meldonium

Full Text:

PDF

References


World Anti-Doping Agency. The 2016 Prohibited List. Available at: http://www.usada.org/wp-content/uploads/wada-2016-prohibited-list-en.pdf (cited 14.11.2016).

USADA. Substance Profile: Meldonium. Secondary Substance Profile: Meldonium; 2016. Available at: http://www.usada.org/meldonium

Bruveris Z, Antane V, Misane I, Rimeicans J, Lusis I, Auzans A, et al. Effects of meldonium on sexual performance, sperm motility, testes morphology and blood biochemical markers in boars. Anim Reprod Sci. 2013 Jan 30;136(4):303-9.

Dambrova M, Liepinsh E, Kalvinsh I. Mildronate: cardioprotective action through carnitine-lowering effect. Trends Cardiovasc Med. 2002;12:275-9.

Sjakste N, Kalvinsh I. Mildronate: an antiischemic drug with multiple indications. Pharmacologyonline. 2006;1:1-18.

Sahartova O, Shatz V, Kalvins I. HPLC analysis of mildronate and itsanalogues in plasma. J Pharm Biomed Anal. 1993;11:1045-7.

Simkhovich BZ, Shutenko ZV, Meirēna DV, Khagi KB, Mežapuķe RJ, Molodchina TN, et al. 3-(2, 2, 2-Trimethylhydrazinium) propionate (thp)-a novel γ-butyrobetaine hydroxylase inhibitor with cardioprotective properties. Biochemical pharmacology. 1988 Jan 15;37(2):195-202.

Zhao Z, Chen J, Peng W, Wang X, Chen Z, Tang H, et al. Single-and multiple-dose pharmacokinetic, safety and tolerability study of mildronate injection in healthy Chinese subjects pharmacokinetic of mildronate injection. Drug research. 2016 May;66(05):251-6.

Peng Y, Yang J, Wang Z, Wang J, Liu Y, Luo Z, et al. Determination of mildronate by LC-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. Journal of Chromatography B. 2010 Feb 15;878(5):551-6.

Zhang J, Cai LJ, Yang J, Zhang QZ, Peng WX. Nonlinear pharmacokinetic properties of mildronate capsules: a randomized, open‐label, single‐and multiple‐dose study in healthy volunteers. Fundamental & clinical pharmacology. 2013 Feb 1;27(1):120-8.

Liepinsh E, Dambrova M. The unusual pharmacokinetics of meldonium: Implications for doping. Pharmacol Res. 2016 Sep;111:100.

Bremer J. Carnitine: Metabolism and functions. Physiological reviews. 1983 Oct 1;63(4):1420-80.

Simkhovich BZ, Shutenko ZV, Meirēna DV, Khagi KB, Mežapuķe RJ, Molodchina TN, et al. 3-(2, 2, 2-Trimethylhydrazinium) propionate (thp)-a novel γ-butyrobetaine hydroxylase inhibitor with cardioprotective properties. Biochemical pharmacology. 1988 Jan 15;37(2):195-202.

Leung IK, Krojer TJ, Kochan GT, Henry L, von Delft F, Claridge TD, et al. Structural and mechanistic studies on γ-butyrobetaine hydroxylase. Chemistry & biology. 2010 Dec 22;17(12):1316-24.

Kuwajima M, Harashima H, Hayashi M, Ise S, Sei M, Lu KM, et al. Pharmacokinetic analysis of the cardioprotective effect of 3-(2, 2, 2-trimethylhydrazinium) propionate in mice: inhibition of carnitine transport in kidney. Journal of Pharmacology and Experimental Therapeutics. 1999 Apr 1;289(1):93-102.

Spaniol M, Brooks H, Auer L, Zimmermann A, Solioz M, Stieger B, et al. Development and characterization of an animal model of carnitine deficiency. The FEBS Journal. 2001 Mar 15;268(6):1876-87.

Dambrova M, Makrecka-Kuka M, Vilskersts R, Makarova E, Kuka J, Liepinsh E. Pharmacological effects of meldonium: biochemical mechanisms and biomarkers of cardiometabolic activity. Pharmacological research. 2016 Nov 30;113:771-80.

Jaudzems K, Kuka J, Gutsaits A, Zinovjevs K, Kalvinsh I, Liepinsh E, et al. Inhibition of carnitine acetyltransferase by mildronate, a regulator of energy metabolism. Journal of enzyme inhibition and medicinal chemistry. 2009 Dec 1;24(6):1269-75.

Oppedisano F, Fanello D, Calvani M, Indiveri C. Interaction of mildronate with the mitochondrial carnitine/acylcarnitine transport protein. Journal of Biochemical and Molecular Toxicology. 2008 Feb 1;22(1):8-14.

Liepinsh E, Vilskersts R, Loca D, Kirjanova O, Pugovichs O, Kalvinsh I, et al. Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction. Journal of cardiovascular pharmacology. 2006 Dec 1;48(6):314-9.

Vilskersts R, Liepinsh E, Mateuszuk L, Grinberga S, Kalvinsh I, Chlopicki S, et al. Mildronate, a regulator of energy metabolism, reduces atherosclerosis in apoE/LDLR–/–mice. Pharmacology. 2009;83(5):287-93.

Hayashi Y, Kirimoto T, Asaka N, Nakano M, Tajima K, Miyake H, et al. Beneficial effects of MET-88, a γ-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction. European journal of pharmacology. 2000 May 3;395(3):217-24.

Dhar PK, Grupp IL, Schwartz A, Grupp G, Matlib MA. Reduction of Carnitine Content by Inhibition of Its Biosynthesis Results in Protection of Isolated Guinea Pig Hearts Against Hypoxic Damage. J Cardiovasc Pharmacol Ther. 1996;1:235-42.

Sokolovska J, Isajevs S, Sugoka O, Sharipova J, Lauberte L, Svirina D et al. Correction of glycaemia and GLUT1 level by mildronate in rat streptozotocin diabetes mellitus model. Cell biochemistry and function. 2011 Jan 1;29(1):55-63.

Sokolovska J, Rumaks J, Karajeva N, Grīnvalde D, Shapirova J, Kluša V, et al. The influence of mildronate on peripheral neuropathy and some characteristics of glucose and lipid metabolism in rat streptozotocin-induced diabetes mellitus model. Biomeditsinskaia khimiia. 2011;57(5):490-500.

Liepinsh E, Vilskersts R, Zvejniece L, Svalbe B, Skapare E, Kuka J, et al. Protective effects of mildronate in an experimental model of type 2 diabetes in goto‐kakizaki rats. British journal of pharmacology. 2009 Aug 1;157(8):1549-56.

Sesti C, Simkhovich BZ, Kalvinsh I, Kloner RA. Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics. Journal of cardiovascular pharmacology. 2006 Mar 1;47(3):493-9.

Dzerve V, Matisone D, Pozdnyakov Y, Oganov R. Mildronate improves the exercise tolerance in patients with stable angina: results of a long term clinical trial. InSeminars in Cardiovascular Medicine. 2010;16(3):1-8.

Sjakste N, Kalvinsh I. Mildronate: an antiischemic drug with multiple indications. Pharmacologyonline. 2006;1:1-18.

Stuart M, Schneider C, Steinbach K. Meldonium use by athletes at the Baku 2015 European Games. Br J Sports Med. 2016;50:694-8.

Görgens C, Guddat S, Dib J, Geyer H, Schänzer W, Thevis M. Mildronate (Meldonium) in professional sports monitoring doping control urinesamples using hydrophilic interaction liquid chromatography high resolution/high accuracy mass spectrometry. Drug Test Anal. 2015;7:973-9.

World Anti-Doping Agency. WADA statement on meldonium notice issued to stakeholders. Available at: https://www.wada-ama.org/en/media/news/2016-04/wada-statement-on-meldonium-notice-issued-to-stakeholders?(cited 12.122016).

Huges D. Meldonium and WADA prohibited lists. Aust Prescr. 2016;39:102.